Prosecution Insights
Last updated: October 27, 2026

Massachusetts Institute of Technology

Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials

174 pending office actions • 92 art units • 159 examiners • 0 of 174 (0%) have an AI response strategy ready • 183 patents granted in the last 365 days

Analysis

Massachusetts Institute of Technology has 188 pending office actions in Biotechnology & Pharmaceuticals. Those matters span 173 distinct examiners and 96 distinct art units, creating a widely distributed prosecution profile. Portfolio oversight should therefore combine strong docket controls with technical and examiner-specific review.

WEHBE, ANNE MARIE SABRINA is the busiest identified examiner, with 3 pending matters. The cluster may warrant targeted examiner research, but it does not define the portfolio’s overall structure. Counsel should use matter-level analysis to account for differences in claim scope, prior art, and art-unit practice.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

174
Total Pending OAs
100
Non-Final OAs
67
Final Rejections
7
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 50 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

29
Overdue
0
Due this week
12
Due this month
5
Due in next 60 days
4
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 50 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (29)Due ≤ 30 days (12)Due ≤ 60 days (5)Due later (4)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

86
Hard (49%)
71
Medium (41%)
16
Easy (9%)
1
Unknown (1%)

Rejection Statute Mix

BucketCases
§101 only1 (1%)
§101 + other22 (13%)
§103 only47 (27%)
§102 only8 (5%)
§112 only12 (7%)
Double-patenting only4 (2%)
Double-patenting + other16 (9%)
Multi-statute (no §101)63 (36%)
No statute on record1 (1%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

141
Life Sciences
81% of docket
5
Information Tech
3% of docket
1
Communications
1% of docket
9
Semiconductors
5% of docket
16
Mechanical / Eng
9% of docket
2
Business / Other
1% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

1,740 h
Manual time on pending OAs
348 h
Time saved (low, 20%)
609 h
Time saved (mid, 35%)
15.2 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
WEHBE, ANNE MARIE SABRINA 3 57.3% +43.3%
RYAN, DOUGLAS CHARLES 3 38.2% +48.4%
MARVICH, MARIA 2 55.0% +28.0%
LI, JUN 2 54.5% +57.0%
MENDEZ, ZULMARIAM 2 66.1% +21.3%
LIPPOLIS, ALEXANDRA ROSE 2 47.2% +63.6%
BELLAH, JEFFREY LAWRENCE 2 100.0% +0.0%
PERRIN, CLARE M 2 68.3% +42.6%
HUTSON, RICHARD G 2 65.1% +52.9%
LEE, JAE W 2 65.6% +38.5%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18564338 CO-MAPPING TRANSCRIPTIONAL STATES AND PROTEIN HISTOLOGY BELLAH, JEFFREY LAWRENCE —

Hard Cases (86)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17941016 Materials and Methods for Biosorption of Micropollutants from Aqueous Solutions PERRIN, CLARE M 140d overdue
17758918 HYBRID CORE MAGNETICS NGUYEN, TUYEN T 110d overdue
16095207 NOVEL CRISPR ENZYMES AND SYSTEMS ZHENG, LI 88d overdue
17439251 ISOLATION, ENRICHMENT AND EXPANSION OF CONE PROGENITOR CELLS AND USES THEREOF MOSS, NATALIE M 70d overdue
18507676 DEVICES, SYSTEMS, METHODS AND COMPUTER-ACCESSIBLE MEDIUM FOR PROVIDING WIRELESS STENT-BASED INTERFACES TO THE NERVOUS SYSTEM HENSON, DEVIN B 51d overdue
18314919 Catalytic process for selective polyolefin hydrogenolysis NGUYEN, TAM M 51d overdue
18438110 MULTIPLANE NANOPHOTONIC VOXEL ENGINE VU, PHU 46d overdue
17440618 CONTROL OF NITROGEN FIXATION IN RHIZOBIA THAT ASSOCIATE WITH CEREALS BARRON, SEAN C 28d overdue

Interview Candidates (20)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17941016 Materials and Methods for Biosorption of Micropollutants from Aqueous Solutions PERRIN, CLARE M 140d overdue
17707951 ENGINEERED ADENO-ASSOCIATED VIRUS CAPSIDS WEHBE, ANNE MARIE SABRINA 99d overdue
18248199 HELITRON MEDIATED GENETIC MODIFICATION LIPPOLIS, ALEXANDRA ROSE 25d overdue
18971207 REACTION SCHEMES INVOLVING ACIDS AND BASES; REACTORS COMPRISING SPATIALLY VARYING CHEMICAL COMPOSITION GRADIENTS; AND ASSOCIATED SYSTEMS AND METHODS LI, JUN 4d overdue
17922126 USE OF REACTOR OUTPUTS TO PURIFY MATERIALS, AND RELATED SYSTEMS LI, JUN 4d overdue
17085937 BACTERIAL DEFENSE SYSTEMS AND METHODS OF IDENTIFYING THEREOF RYAN, DOUGLAS CHARLES 3d overdue
16954032 CAS12A SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED RNA BASE EDITING HUTSON, RICHARD G 20d
17786168 GENOME EDITING USING REVERSE TRANSCRIPTASE ENABLED AND FULLY ACTIVE CRISPR COMPLEXES LEE, JAE W 33d

Top Art Units

Art UnitApps
1636 7
1631 6
1637 6
1634 5
1635 5
1652 5
1632 5
1684 5
1732 4
1794 4

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19449304 ENGINEERED MUSCLE TARGETING COMPOSITIONS MARVICH, MARIA 1634 §112 Non-Final OA — Pending Jan 14, 2026
19390128 ENGINEERED ADENO-ASSOCIATED VIRUS CAPSIDS WEHBE, ANNE MARIE SABRINA 1634 §103 Final Rejection — Pending Nov 14, 2025
19355982 ENGINEERED MUSCLE TARGETING COMPOSITIONS MARVICH, MARIA 1634 §112DP Non-Final OA — Pending Oct 10, 2025
19156119 DETERMINATION OF PATH WITH ENHANCED OR OPTIMIZED COLLECTION AND TIME IN DYNAMIC ENVIRONMENTS KAN, YURI 3662 §101§112 Non-Final OA — Pending Aug 13, 2025
19290464 FINGER INSERTS FOR A NAILFOLD IMAGING DEVICE BROWN, HELENE CATHERINE 3797 §103Other Non-Final OA — Pending Aug 05, 2025
19100973 ROBOT AVATAR GE, JIN 2619 §102 Non-Final OA — Pending Feb 04, 2025
18996502 DEFORMATION SENSING AND OBJECT IDENTIFICATION WITH COLOR-DYNAMIC MECHANO-RESPONSIVE PHOTONIC MATERIALS AHMED, JAMIL 2877 §103 Non-Final OA — Pending Jan 17, 2025
19011409 BRANCHED MULTI-FUNCTIONAL MACROMONOMERS AND RELATED POLYMERS AND USES THEREOF DAVIS, BRIAN J 1614 DP Non-Final OA — Pending Jan 06, 2025
18989747 LOW-DEFECT FABRICATION OF COMPOSITE MATERIALS GOFF II, JOHN L 1746 §102§103§112DP Non-Final OA — Pending Dec 20, 2024
18983556 THREE-DIMENSIONAL MACHINE KNITTING OF ELECTRONIC TEXTILE FOR ACTIVITY RECOGNITION AND BIOMECHANICAL MONITORING MUSSER, BARBARA J 1746 §101§103 Non-Final OA — Pending Dec 17, 2024
18971207 REACTION SCHEMES INVOLVING ACIDS AND BASES; REACTORS COMPRISING SPATIALLY VARYING CHEMICAL COMPOSITION GRADIENTS; AND ASSOCIATED SYSTEMS AND METHODS LI, JUN 1732 §103Other Non-Final OA 4d overdue Pending Dec 06, 2024
18965935 NOVEL TYPE VI CRISPR ENZYMES AND SYSTEMS RYAN, DOUGLAS CHARLES 1635 §112 Non-Final OA — Pending Dec 02, 2024
18863758 METHOD AND APPARATUS FOR DETERMINING ABNORMAL CARDIAC CONDITIONS NON-INVASIVELY KRETZER, KYLE W. 3791 §101§102§103§112 Non-Final OA — Pending Nov 07, 2024
18862237 BULK NANOCOMPOSITE MATERIALS AND METHODS FOR MAKING THESE GOLDEN, CHINESSA T 1788 §103 Non-Final OA — Pending Nov 01, 2024
18932763 PROGRAMMABLE NUCLEASE-PEPTIDASE COMPOSITIONS KIEFER, DALTON EDWARD 1652 §102§103§112Other Non-Final OA — Pending Oct 31, 2024
18845790 OPTICALLY ADDRESSABLE MOLECULAR-SPIN QUBIT DILUTED IN A HOST MATRIX BROMELL, ALEXANDRIA Y 2156 §101 Non-Final OA — Pending Sep 10, 2024
18828425 STRONG, MODULAR, AND PROGRAMMABLE PLATE LATTICES HAVING KIRIGAMI CORRUGATIONS COOK, WILLIAM J 1784 §103§112 Non-Final OA — Pending Sep 09, 2024
18821462 POLYANION COATED LIPID NANOPARTICLES AND METHODS OF USE THEREOF PURDY, KYLE A 1611 §103 Final Rejection — Pending Aug 30, 2024
18811452 COMBINATION THERAPIES AND METHODS OF USE THEREOF FOR TREATING CANCER GEMBEH, SHIRLEY V 1615 DP Non-Final OA — Pending Aug 21, 2024
18838586 NANO-PHASE SEPARATING NI POWDER AND THE METHODOLOGY TO IDENTIFY THEM YANG, JIE 1734 §102§103§112Other Non-Final OA — Pending Aug 14, 2024
18801075 PARTICLES WITH COVALENTLY LIPID-BOUND IMMUNOSTIMULATORY AGENTS RICCI, CRAIG D 1611 §103 Final Rejection — Pending Aug 12, 2024
18798428 Opto-Electronic Chiplets for Scalable Coherent Interconnects to Zero-Change VLSI Electronics PAK, SUNG H 2874 §102§103 Non-Final OA — Pending Aug 08, 2024
18837046 BOTTOM GARMENT WITH EMBEDDED HARNESS LEWIS, KIM M 3786 §102§103 Final Rejection — Pending Aug 08, 2024
18833448 SYSTEMS AND METHODS FOR OSMOTICALLY ASSISTED REVERSE OSMOSIS CONFIGURATIONS MENON, KRISHNAN S 1771 §102§103§112 Non-Final OA — Pending Jul 26, 2024
18770880 HEME-BINDING SMALL PEPTIDE MARTINEZ, TARA L 1654 §102§103 Non-Final OA — Pending Jul 12, 2024
18727623 AN IMPLANTABLE CLOSED-LOOP SYSTEM FOR MONITORING AND TREATMENT DIOP, FATIMATA SAHRA 3783 §103 Non-Final OA — Pending Jul 09, 2024
18767197 SUPERCONDUCTING CABLE JOINT AND RELATED TECHNIQUES LEE, PETE T 2847 §102§103 Non-Final OA — Pending Jul 09, 2024
18727019 POLYIMIDAZOLIUM-BASED CATIONIC ANTIMICROBIAL POLYMERS FOR NOVEL MASTITIS PROPHYLACTIC SOLUTIONS HOLLOMAN, NANNETTE 1612 §103 Final Rejection — Pending Jul 05, 2024
18714142 POLY(BETA-AMINO ESTER) MICROPARTICLES FOR MICRONUTRIENT FORTIFICATION WORSHAM, JESSICA N 1615 §112 Non-Final OA — Pending May 29, 2024
18674715 SMALL MOLECULE INHIBITORS OF INTERLEUKIN-4 RAHMANI, NILOOFAR 1691 §102 Non-Final OA — Pending May 24, 2024
18655491 GEOMETRICALLY-ACCOMMODATING HEART VALVE REPLACEMENT DEVICE GHERBI, SUZETTE JAIME J — §102§103Other Non-Final OA — Pending May 06, 2024
18707798 PARTICLES CONTAINING POLLUTANT-CAPTURING MICELLES AND RELATED METHODS NGUYEN, BOI-LIEN THI 1779 §102§103§112 Non-Final OA — Pending May 06, 2024
18654474 ADDITIVE MANUFACTURING USING BONDING OF VOXELS AND RELATED SYSTEMS, DEVICES, AND ARTICLES WIECZOREK, MICHAEL P 1712 §102§103 Final Rejection 5d overdue Pending May 03, 2024
18652600 CARBON SEQUESTRATION MATERIALS AND RELATED SYSTEMS, ARTICLES, AND METHODS MCCLAIN, STARFARI TESHAWN 1736 §102§103 Non-Final OA — Pending May 01, 2024
18649438 USE OF ACIDIC ELECTROLYTE CATIONS FOR SELECTIVE ELECTROCHEMICAL CO2 AND CO CONVERSIONS TO METHANOL WONG, EDNA 1795 §103§112 Non-Final OA — Pending Apr 29, 2024
18698888 LIPID NANOPARTICLES FOR DRUG DELIVERY TO MICROGLIA IN THE BRAIN VANHORN, ABIGAIL LOUISE 1636 §103§112DP Non-Final OA — Pending Apr 05, 2024
18698929 ENGINEERED CARDIAC MUSCLE COMPOSITIONS SINGH, ANOOP KUMAR 1632 §102§103§112DP Non-Final OA — Pending Apr 05, 2024
18623432 A CARBON-EFFICIENT BICARBONATE ELECTROLYZER RIPA, BRYAN D 1794 §102§103 Non-Final OA — Pending Apr 01, 2024
18623523 Diels-Alder coupling for cycloalkane production for sustainable aviation fuel CEPLUCH, ALYSSA L 1772 §103 Final Rejection 17d overdue Pending Apr 01, 2024
18604009 Tactile Blood Pressure Imager PARK, PATRICIA JOO YOUNG 3798 §103 Final Rejection 49d overdue Pending Mar 13, 2024
18689897 ENGINEERED MUSCLE AND CENTRAL NERVOUS SYSTEM COMPOSITIONS PYLA, EVELYN Y 1633 §101§102§103§112 Non-Final OA — Pending Mar 07, 2024
18690033 A MICROBIAL ELECTROCHEMICAL TECHNOLOGY TO DETECT AND DEGRADE ORGANOPHOSPHATE PESTICIDES FAN, WEIHUA 1663 §103 Non-Final OA 8d overdue Pending Mar 07, 2024
18689764 INTERLAYERS FOR CHARGE TRANSFER-MEDIATED TRIPLET EXCITON TRANSFER FROM A SINGLET EXCITON FISSION MATERIAL TO AN INORGANIC SEMICONDUCTOR TRINH, THANH TRUC 1726 §103 Non-Final OA — Pending Mar 06, 2024
18590218 GENERATION OF QUANTUM CONTROL PULSES AND RELATED SYSTEMS ZENG, WENWEI 2146 §101§103§112 Non-Final OA — Pending Feb 28, 2024
18687564 ALTERNATIVE NANOPOROUS NETWORK MATERIALS AND PROCESSES VO, HAI 1788 §102§103Other Non-Final OA 70d Pending Feb 28, 2024
18440702 ELECTROCHEMICAL DEVICES OR SYSTEMS COMPRISING REDOX-FUNCTIONALIZED ELECTRODES AND USES THEREOF SMITH, NICHOLAS A 1752 §102 Non-Final OA — Pending Feb 13, 2024
18439487 COMPOSITIONS AND METHODS FOR MOLECULAR MEMORY STORAGE AND RETRIEVAL OLSON, ALEXANDRA NADINE 1684 §102 Non-Final OA — Pending Feb 12, 2024
18438110 MULTIPLANE NANOPHOTONIC VOXEL ENGINE VU, PHU 2871 §102§103 Non-Final OA 46d overdue Pending Feb 09, 2024
18432439 Biosensors in Human Gut Organoids MOLOYE, TITILAYO 1632 §103 Final Rejection — Pending Feb 05, 2024
18294259 DYNAMICALLY RECONFIGURABLE ARCHITECTURES FOR QUANTUM INFORMATION AND SIMULATION STOFFA, WYATT A — §103§112 Non-Final OA — Pending Feb 01, 2024

View all 174 →

Managing Massachusetts Institute of Technology's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Massachusetts Institute of Technology have?

Massachusetts Institute of Technology has 174 pending office actions as of October 2026, spread across 92 art units and 159 examiners.

Which USPTO examiner handles the most Massachusetts Institute of Technology applications?

Anne Marie Sabrina Wehbe has the most, with 3 of Massachusetts Institute of Technology's pending office actions.

What technology area are Massachusetts Institute of Technology's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month